tradingkey.logo

mrk

MRK

75.970USD

-1.680-2.16%
종가 05/09, 16:00ET시세는 15분 지연됩니다
191.15B시가총액
11.17P/E TTM

mrk

75.970

-1.680-2.16%
자세한 내용은 Merck & Co Inc 회사
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company's segments include Pharmaceutical and Animal Health. Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells its human health vaccines primarily to physicians, wholesalers, distributors and government entities. Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. It sells its products to veterinarians, distributors, animal producers, farmers and pet owners.
회사 정보
회사 코드MRK
회사 이름Merck & Co Inc
상장일Jan 01, 1941
설립일1970
CEOMr. Robert M. (Rob) Davis
직원 수75000
유형Ordinary Share
회계 연도 종료Jan 01
주소126 East Lincoln Avenue
도시RAHWAY
증권 거래소NYSE Consolidated
국가United States of America
우편 번호07065
전화19087404000
웹사이트https://www.merck.com/
회사 코드MRK
상장일Jan 01, 1941
설립일1970
회사 임원
이름
이름/직위
직위
주식 보유
변동
Mr. Robert M. (Rob) Davis
Mr. Robert M. (Rob) Davis
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
443.60K
--
Mr. Sanat Chattopadhyay
Mr. Sanat Chattopadhyay
Executive Vice President and President - Merck Manufacturing Division
Executive Vice President and President - Merck Manufacturing Division
185.33K
+17.90%
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Executive Vice President, President - Merck Research Laboratories
Executive Vice President, President - Merck Research Laboratories
79.59K
+0.92%
Ms. Caroline Litchfield
Ms. Caroline Litchfield
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
74.34K
--
Mr. Chirfi Guindo
Mr. Chirfi Guindo
Senior Vice President, Chief Marketing Officer - Human Health
Senior Vice President, Chief Marketing Officer - Human Health
66.61K
+73.22%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Executive Vice President, General Counsel
Executive Vice President, General Counsel
53.42K
+90.81%
Mr. Joseph Edward Romanelli
Mr. Joseph Edward Romanelli
Senior Vice President, President - MSD International Human Health
Senior Vice President, President - MSD International Human Health
22.91K
+5.27%
Ms. Patricia F. Russo
Ms. Patricia F. Russo
Independent Director
Independent Director
13.15K
--
Mr. Thomas Henry (Tom) Glocer, J.D.
Mr. Thomas Henry (Tom) Glocer, J.D.
Lead Independent Director
Lead Independent Director
5.10K
--
Mr. Inge G. Thulin
Mr. Inge G. Thulin
Independent Director
Independent Director
2.93K
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Robert M. (Rob) Davis
Mr. Robert M. (Rob) Davis
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
443.60K
--
Mr. Sanat Chattopadhyay
Mr. Sanat Chattopadhyay
Executive Vice President and President - Merck Manufacturing Division
Executive Vice President and President - Merck Manufacturing Division
185.33K
+17.90%
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Executive Vice President, President - Merck Research Laboratories
Executive Vice President, President - Merck Research Laboratories
79.59K
+0.92%
Ms. Caroline Litchfield
Ms. Caroline Litchfield
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
74.34K
--
Mr. Chirfi Guindo
Mr. Chirfi Guindo
Senior Vice President, Chief Marketing Officer - Human Health
Senior Vice President, Chief Marketing Officer - Human Health
66.61K
+73.22%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Executive Vice President, General Counsel
Executive Vice President, General Counsel
53.42K
+90.81%
수익 분석
통화: USD업데이트 시간: Sun, Apr 6
통화: USD업데이트 시간: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
사업별USD
이름
수익
비율
Oncology-Keytruda
29.48B
45.95%
Vaccines -Gardasil/Gardasil
8.58B
13.38%
Animal Health-Livestock
3.46B
5.39%
Other pharmaceutical
2.51B
3.91%
Vaccines -ProQuad/M-M-R II/Varivax
2.48B
3.87%
Other
17.65B
27.50%
지역별USD
이름
수익
비율
United States
32.28B
50.30%
Europe, Middle East and Africa
14.04B
21.88%
China
5.49B
8.56%
Latin America
3.46B
5.39%
Japan
3.28B
5.11%
Other
5.62B
8.75%
사업별
지역별
사업별USD
이름
수익
비율
Oncology-Keytruda
29.48B
45.95%
Vaccines -Gardasil/Gardasil
8.58B
13.38%
Animal Health-Livestock
3.46B
5.39%
Other pharmaceutical
2.51B
3.91%
Vaccines -ProQuad/M-M-R II/Varivax
2.48B
3.87%
Other
17.65B
27.50%
주주
업데이트 시간: Sat, Apr 26
업데이트 시간: Sat, Apr 26
주주 통계
유형
주주 통계
주주
비율
The Vanguard Group, Inc.
10.01%
BlackRock Institutional Trust Company, N.A.
5.87%
State Street Global Advisors (US)
4.82%
Wellington Management Company, LLP
3.22%
Geode Capital Management, L.L.C.
2.44%
Other
73.66%
주주 통계
주주
비율
The Vanguard Group, Inc.
10.01%
BlackRock Institutional Trust Company, N.A.
5.87%
State Street Global Advisors (US)
4.82%
Wellington Management Company, LLP
3.22%
Geode Capital Management, L.L.C.
2.44%
Other
73.66%
유형
주주
비율
Investment Advisor/Hedge Fund
35.95%
Investment Advisor
32.98%
Research Firm
3.53%
Pension Fund
2.94%
Bank and Trust
2.47%
Hedge Fund
1.53%
Sovereign Wealth Fund
1.50%
Insurance Company
0.71%
Family Office
0.11%
Other
18.30%
기관 주식 보유
업데이트 시간: Thu, Feb 20
업데이트 시간: Thu, Feb 20
보고 기간
기관 수
보유 주식
비율
변동
2025Q1
5376
2.04B
81.37%
-986.87K
2024Q4
5410
2.04B
80.88%
+11.87M
2024Q3
5200
2.01B
79.47%
-7.96M
2024Q2
5181
2.01B
79.28%
-4.86M
2024Q1
5154
2.00B
78.88%
-6.10M
2023Q4
5065
1.99B
78.60%
+584.81K
2023Q3
4871
1.98B
78.17%
-32.03M
2023Q2
4864
2.00B
78.94%
-18.54M
2023Q1
4818
1.99B
78.43%
-16.95M
2022Q4
4785
1.98B
77.94%
-5.23M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
The Vanguard Group, Inc.
253.26M
10.03%
+3.27M
+1.31%
Feb 28, 2025
BlackRock Institutional Trust Company, N.A.
143.39M
5.68%
+10.26M
+7.71%
Dec 31, 2024
State Street Global Advisors (US)
120.91M
4.79%
+1.88M
+1.58%
Dec 31, 2024
Wellington Management Company, LLP
80.74M
3.2%
+4.93M
+6.51%
Dec 31, 2024
Geode Capital Management, L.L.C.
61.18M
2.42%
+2.03M
+3.43%
Dec 31, 2024
Charles Schwab Investment Management, Inc.
20.13M
0.8%
+1.32M
+7.01%
Dec 31, 2024
Norges Bank Investment Management (NBIM)
34.98M
1.38%
+1.17M
+3.47%
Dec 31, 2024
Fidelity Management & Research Company LLC
33.58M
1.33%
-11.95M
-26.24%
Dec 31, 2024
BofA Global Research (US)
23.08M
0.91%
-1.38M
-5.65%
Dec 31, 2024
BlackRock Asset Management Ireland Limited
21.22M
0.84%
+1.34M
+6.77%
Dec 31, 2024
더 보기
관련 ETF
업데이트 시간: Tue, May 6
업데이트 시간: Tue, May 6
이름
비율
FT Vest DJIA Dogs 10 Target Income ETF
11.99%
First Trust NASDAQ Pharmaceuticals ETF
7.94%
Invesco Dow Jones Industrial Average Dividend ETF
5.92%
VanEck Pharmaceutical ETF
5.04%
TBG Dividend Focus ETF
5.01%
Invesco Pharmaceuticals ETF
4.89%
VictoryShares Free Cash Flow ETF
4.51%
Vaneck Durable High Dividend ETF
4.48%
Amplify Weight Loss Drug & Treatment ETF
4.43%
VictoryShares Free Cash Flow Growth ETF
4.3%
더 보기
FT Vest DJIA Dogs 10 Target Income ETF
비율11.99%
First Trust NASDAQ Pharmaceuticals ETF
비율7.94%
Invesco Dow Jones Industrial Average Dividend ETF
비율5.92%
VanEck Pharmaceutical ETF
비율5.04%
TBG Dividend Focus ETF
비율5.01%
Invesco Pharmaceuticals ETF
비율4.89%
VictoryShares Free Cash Flow ETF
비율4.51%
Vaneck Durable High Dividend ETF
비율4.48%
Amplify Weight Loss Drug & Treatment ETF
비율4.43%
VictoryShares Free Cash Flow Growth ETF
비율4.3%
주식 배당금
지난 5년 동안 총 35.12B USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
Jan 28, 2025
MRK.NB Interim Cash Dividend of gross USD 0.81 paid on Apr 07, 2025 going ex on Mar 17, 2025
Mar 17, 2025
Apr 07, 2025
Mar 17, 2025
Nov 19, 2024
MRK.NB Final Cash Dividend of gross USD 0.81 paid on Jan 08, 2025 going ex on Dec 16, 2024
Dec 16, 2024
Jan 08, 2025
Dec 16, 2024
Jul 23, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Oct 07, 2024 going ex on Sep 16, 2024
Sep 16, 2024
Oct 07, 2024
Sep 16, 2024
May 29, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Jul 08, 2024 going ex on Jun 17, 2024
Jun 17, 2024
Jul 08, 2024
Jun 17, 2024
Jan 23, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Apr 05, 2024 going ex on Mar 14, 2024
Mar 15, 2024
Apr 05, 2024
Mar 14, 2024
Nov 28, 2023
MRK.NB Final Cash Dividend of gross USD 0.77 paid on Jan 08, 2024 going ex on Dec 14, 2023
Dec 15, 2023
Jan 08, 2024
Dec 14, 2023
Jul 25, 2023
MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Oct 06, 2023 going ex on Sep 14, 2023
Sep 15, 2023
Oct 06, 2023
Sep 14, 2023
May 23, 2023
MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Jul 10, 2023 going ex on Jun 14, 2023
Jun 15, 2023
Jul 10, 2023
Jun 14, 2023
Jan 24, 2023
MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Apr 10, 2023 going ex on Mar 14, 2023
Mar 15, 2023
Apr 10, 2023
Mar 14, 2023
Nov 30, 2022
MRK.NB Final Cash Dividend of gross USD 0.73 paid on Jan 09, 2023 going ex on Dec 14, 2022
Dec 15, 2022
Jan 09, 2023
Dec 14, 2022
더 보기
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
tradingkey.logo
tradingkey.logo
당일 거래 데이터는 Refinitiv에서 제공하며, 이용 약관이 적용됩니다. 역사적 및 현재 종가 데이터는 Refinitiv에서 제공합니다. 모든 시세는 현지 거래소 시간 기준입니다. 미국 주식 시세의 실시간 마지막 거래 데이터는 Nasdaq을 통해 보고된 거래만 반영됩니다. 당일 거래 데이터는 최소 15분 지연되거나 거래소 요구 사항에 따라 다를 수 있습니다.
* 참고자료, 분석 및 트레이딩 전략은 제3자 제공업체인 Trading Central에서 제공하며, 분석가의 독립적인 평가와 판단에 기반한 시각으로, 투자자의 투자 목표와 재정 상황은 고려되지 않습니다.
위험 경고: 저희 웹사이트와 모바일 앱은 특정 투자 상품에 대한 일반적인 정보만을 제공합니다. Finsights는 재정적 조언이나 투자 상품에 대한 추천을 제공하지 않으며, 이러한 정보 제공이 Finsights가 금융 조언이나 추천을 제공하는 것으로 해석되어서는 안 됩니다.
투자 상품은 투자 원금 손실을 포함한 상당한 투자 위험에 노출되어 있으며, 모든 사람에게 적합하지 않을 수 있습니다. 투자 상품의 과거 성과는 미래 성과를 보장하지 않습니다.
Finsights는 제3자 광고주나 제휴사가 저희 웹사이트나 모바일 앱 또는 그 일부에 광고를 게재하거나 전달할 수 있도록 허용할 수 있으며, 사용자가 광고와 상호작용하는 방식에 따라 이들로부터 보상을 받을 수 있습니다.
© 저작권: FINSIGHTS MEDIA PTE. LTD. 모든 권리 보유